

Myeloma 2022: day two highlights
Sep 2, 2022
Gareth Morgan, Rafael Fonseca, Leif Bergsagel, and Keith Stewart discuss highlights from day two of the Myeloma 2022 meeting, covering topics such as BCL2 inhibitors, T-cell exhaustion, immunotherapy, targeted therapies, combination therapies, minimal residual disease, and the efficacy of Carti therapy in managing melon.
Chapters
Transcript
Episode notes
1 2 3 4 5
Introduction
00:00 • 2min
Treatment Options and Challenges in Myeloma
02:25 • 4min
Exploring the Effectiveness of Targeted Therapies for Myeloma and Considering Alternative Approaches
06:26 • 2min
The Importance of Combination Therapies and the Shift Towards Minimal Residual Disease
08:09 • 2min
Carti Therapy: A Revolutionary Treatment for Melon
09:42 • 2min